Asahi Kasei, Teijin Seek New Delivery Methods For Osteo Drugs
This article was originally published in PharmAsia News
At least two Japanese drug makers, Asahi Kasei and Teijin, are focusing on new ways to deliver osteoporosis drugs, one using skin patches, the other a gelatin.
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.